|本期目录/Table of Contents|

[1]洪铁艳,余正平.来那度胺联合地塞米松方案对复发难治多发性骨髓瘤的治疗作用并文献复习[J].医学研究与战创伤救治(原医学研究生学报),2014,16(06):597-599，618.[doi:10.3969/j.issn.1672-271X.2014.06.011]
　HONG Tie-yan,YU Zheng-ping..The efficacy and safety of treatment of relapsed and refractory multiple myeloma combining lenalidomide with dexamethasone[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(06):597-599，618.[doi:10.3969/j.issn.1672-271X.2014.06.011]
点击复制

来那度胺联合地塞米松方案对复发难治多发性骨髓瘤的治疗作用并文献复习()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第16卷
期数:
2014年06期
页码:
597-599，618
栏目:
出版日期:
2014-11-20

文章信息/Info

Title:
The efficacy and safety of treatment of relapsed and refractory multiple myeloma combining lenalidomide with dexamethasone
作者:
洪铁艳1; 余正平2
1.211102 江苏南京，东南大学医学院附属南京同仁医院血液肿瘤科；2.210009 江苏南京，东南大学医学院附属中大医院血液科
Author(s):
HONG Tie-yan1; YU Zheng-ping2.
1.Department of Hematology & Oncology,the Affiliated Nanjing Tongren Hospital of Southeast University Medical College,Nanjing,Jiangsu 211102,China;2.Department of Hematology,the Affiliated Zhongda Hospital of Southeast University Medical College,Nanjing
关键词:
来那度胺; 复发难治多发性骨髓瘤; 地塞米松
Keywords:
lenalidomide;  relapsed and refractory multiple myeloma;  dexamethasone
分类号:
R733.3
DOI:
10.3969/j.issn.1672-271X.2014.06.011
文献标志码:
A
摘要:
目的 探讨来那度胺联合地塞米松治疗复发难治多发性骨髓瘤的疗效。方法 10例复发难治多发性骨髓瘤患者，一线化疗耐受，予来那度胺联合地塞米松方案治疗。结果 应用该方案后，患者疾病均得到控制，M蛋白与β2微球蛋白显著下降，无完全缓解，部分缓解率为40%；至2014年7月5例进展患者的无进展生存期为8个月(5～10个月)；其余5例病 情均稳定。该方案相关毒性反应较轻，患者能够耐受。结论 来那度胺联合地塞米松治疗复发难治多发性骨髓瘤患者，具有一定疗效，患者耐受性好。
Abstract:
Objective This study was to determine the efficacy and safety of treatment of relapsed and refractory multiple myeloma combining lenalidomide with dexamethasone.Methods 10 patients with relapsed and refractory multiple myeloma who failed for first line chemotherapy were treated with lenalidomide and dexamethasone based chemotherapy.Results After the treatment,the levels of immunoglobulin and β2-microglobulin were reduced significantly.The disease control rate was 100%,the partial response rate was 40%.The disease progressed in 5 patients by July 2014,and the median duration of progression-free was 8 months (range,5-10 months).Treatment-related toxicities were tolerant. Conclusion Lenalidomide-dexamethasone appears effective and tolerable in treating patients with relapsed and refractory multiple myeloma.

参考文献/References:

[1]Palumbo A，Anderson K.Multiple myeloma[J].N Engl J Med,2011,364(11):1046-1060.
[2]中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南[J].中华内科杂志,2008,47(10):869-872.
[3]李 娟.《中国多发性骨髓瘤诊治指南(2013年修订)》疗效标准部分的解读[J].中华内科杂志,2013,52(9):798-800.
[4]皋文君,刘砚燕,袁长蓉,等.国际肿瘤化疗药物不良反应评价系统-通用不良反应术语标准(4.0版)[J].肿瘤,2012,32(2):142-144.
[5]Richardson PG,Xie W,Jagannath S,et al.A phase 2 trial of lenalidomide,bortezomib,and dexamethasone in patients with relapsed and relapsed/refractory myeloma[J].Blood,2014,123(10):1461-1469.
[6]奚 昊,侯 健,袁振刚,等.VTD方案治疗复发难治性多发性骨髓瘤36例[J].东南国防医药,2010,12(1):36-38.
[7]Ocio EM,Richardson PG,Rajkumar SV,et al.New drugs and novel mechanisms of action in multiple myeloma in 2013:a report from the International Myeloma Working Group (IMWG)[J].Leukemia,2014,28(3):525-542.
[8]Dimopoulos M,Spencer A,Attal M,et al.Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma[J].N Engl J Med,2007,357(21):2123-2132.
[9]McCarthy PL,Owzar K,Hofmeister CC,et al.Lenalidomide after stem-cell transplantation for multiple myeloma[J].N Engl J Med,2012,366(19):1770-1781.
[10]Attal M,Lauwers-Cances V,Marit G,et al.Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J].N Engl J Med,2012,366(19):1782- 1791.
[11]Palumbo A,Hajek R,Delforge M,et al.Continuous lenalidomide treatment for newly diagnosed multiple myeloma[J].N Engl J Med,2012,366(19):1759-1769.
[12]Kim K,Kim SJ,Voelter V,et al.Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients [J].Ann Hematol,2014,93(1):113-121.
[13]Hou J,Du X,Jin J,et al.A multicenter,open-label,phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma:the MM-021 trial[J].J Hematol Oncol,2013,6(1):41.
[14]Bataille R,Annweiler C,Beauchet O.Multiple myeloma international staging system:“staging” or simply “aging” system?[J]Clin Lymphoma Myeloma Leuk,2013,13(6):635-637.
[15]Sun HL,Atenafu EG,Yeboah E,et al.Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone[J].Leuk Lymphoma,2014,7:1-8.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2014-11-20